Jaguar’s name is now Jaguar Health!
On Monday, July 31, the merger of Jaguar Animal Health and Napo Pharmaceuticals became effective. Napo focuses on the development and commercialization of proprietary gastrointestinal pharmaceuticals for the global human marketplace from sustainably derived plants used traditionally in rainforest areas. As a result of the merger, Jaguar’s name is now Jaguar Health, Inc., and Napo is a wholly-owned subsidiary of Jaguar, focused on the continuing commercialization of its Mytesi® (crofelemer) product, which is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Serving a Broad Range of Species
Our products will serve companion animals,
horses and production animals with prescription
and non-prescription products globally.
Access to Powerful, Natural Compounds
Jaguar maintains an exclusive, worldwide
license to a large medicinal plant library for
Committed to Animal Health
We are focused on the development &
commercialization of animal health
solutions that are naturally derived
& sustainably harvested.
In conjunction with Napo Pharmaceuticals, our new subsidiary, Jaguar Health is focused on developing and commercializing a range of first-in-class gastrointestinal prescription products for humans and animals, as well as non-prescription gastrointestinal products for animals.
We are committed to identifying human and animal health market opportunities where we can develop targeted products that leverage our broad intellectual property portfolio, deep pipeline and extensive botanical library.